What is Arkuda Therapeutics?
Arkuda Therapeutics is a biotechnology firm dedicated to pioneering new medicines by leveraging advanced insights into lysosomal biology. The company's primary focus is on addressing neurodegenerative conditions, with its lead program targeting progranulin deficiency and lysosomal dysfunction in GRN-related frontotemporal dementia (FTD-GRN). Beyond this specific genetic subtype, Arkuda is exploring the broader therapeutic potential of its compounds in genetically-defined Parkinson's disease and other neurodegenerative disorders, aiming to fundamentally alter disease trajectories.
How much funding has Arkuda Therapeutics raised?
Arkuda Therapeutics has raised a total of $108M across 2 funding rounds:
Series A
$44M
Series B
$64M
Series A (2019): $44M with participation from Tekla Capital Management LLC, Pfizer Ventures, Atlas Venture, and BioInnovation Capital
Series B (2022): $64M led by Surveyor Capital, Eli Lilly, Cormorant Asset Management, and Pivotal Bioventure Partners
Key Investors in Arkuda Therapeutics
Tekla Capital Management LLC
Tekla Capital Management LLC is a life sciences investment firm that provides financial resources to innovative companies in the biotech sector. They focus on supporting promising ventures and capturing investment opportunities within the life sciences industry.
Pfizer Ventures
Pfizer Ventures is the venture capital arm of Pfizer, a global biopharmaceutical company. They invest in emerging companies that align with Pfizer's strategic interests in developing innovative medicines and healthcare solutions.
Atlas Venture
Atlas Venture is an early-stage venture capital firm specializing in the biotechnology sector. They partner with entrepreneurs to build groundbreaking companies focused on translating scientific discoveries into life-changing medicines.
What's next for Arkuda Therapeutics?
With its recent major strategic investment, Arkuda Therapeutics is well-positioned to accelerate its drug development pipeline and expand its research into other neurodegenerative diseases. The company's focus on lysosomal biology and genetically-defined patient populations suggests a strategy aimed at precision medicine. Future endeavors will likely involve advancing its lead programs through clinical trials and further validating the therapeutic potential of its platform across a spectrum of neurological conditions. This latest financing round signals strong investor confidence in Arkuda's scientific approach and its potential to deliver transformative treatments.
See full Arkuda Therapeutics company page
